The treatment of chronic hepatitis C (CHC) has been revolutionized in an era of all-oral
direct-acting antivirals (DAAs) since 2014. Satisfactory treatment efficacy and tolerability can …

Abstract Background Hepatitis C (HCV)-induced decompensated cirrhosis warrants liver
transplantation (LT) as the only ultimate solution. These patients experience liver …

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality
worldwide. The Brazilian Society of Hepatology (SBH) published in 2015 its first …

Survival following liver transplantation has changed dramatically owing to improvement in
surgical techniques, peri-operative care and optimal immunosuppressive therapy. Post-Liver …

Long‐term effects on cirrhosis and portal hypertension of direct antiviral agent (DAA)‐based
eradication of hepatitis C virus (HCV) are still under debate. We analysed dynamics of liver …

Abstract On June 8, 2018, an NS3/4A protease inhibitor called danoprevir was approved in
China to treat the infections of HCV genotype (GT) 1b–the most common HCV genotype …

The introduction of highly potent direct‐acting antivirals (DAAs) has revolutionized hepatitis
C virus treatment. Nevertheless, viral eradication worldwide remains a challenge also in the …

AIM To evaluate waiting list (WL) registration and liver transplantation (LT) rates in patients
with hepatitis C virus (HCV)-related cirrhosis since the introduction of direct-acting antivirals …

Background The benefits of treatment of hepatitis C virus with direct-acting antiviral drugs in
patients with decompensated liver cirrhosis (DLC) are still unclear. Aim To evaluate the …

The rapid progress in the development of direct-acting antiviral agents for hepatitis C has
allowed the vast majority of patients to receive all oral therapy that will eliminate their virus …